Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

Nov 30, 2023 4:59pm EST

Aptose Reports Results for the Third Quarter 2023

Nov 09, 2023 4:00pm EST

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Nov 02, 2023 9:00am EDT

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Oct 30, 2023 9:15am EDT

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

Oct 26, 2023 7:11am EDT

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Oct 23, 2023 7:30am EDT

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Oct 16, 2023 7:30am EDT

Aptose to Present at the Cantor Global Healthcare Conference

Sep 18, 2023 7:45am EDT

Aptose to Present at the Cantor Global Healthcare Conference

Sep 18, 2023 7:45am EDT

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

Sep 06, 2023 7:45am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...32
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences